Compared with GC patients with lower expression of MYLK, MYL9, LUM, and CAV1 (GEO, n = 217; TCGA, n = 190), these patients with high expression of key genes (n = 216, GEO; n = 190, TCGA) had significantly poorer prognosis (p < 0.05, Figures 2A–D and Supplementary Figures S1A-D). This evidence concerns the gene MYL9 and gastric cancer.